TCMP
UTHR icon

Thrive Capital Management (Pennsylvania)’s United Therapeutics UTHR Stock Holding History

Thrive Capital Management (Pennsylvania)’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.24M Buy
7,824
+672
+9% +$378K 0.8% 58
2026
Q1 		$4.24M Sell
7,152
-159
-2% -$79.2K 0.93% 38
2025
Q4 		$3.56M Buy
+7,311
New +$3.4M 0.79% 61

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Thrive Capital Management (Pennsylvania)'s UTHR Position: Q2 2026 in Review

Thrive Capital Management (Pennsylvania) increased its United Therapeutics (UTHR) stake by 9.4% in Q2 2026, buying an estimated $378K and bringing the position to 7,824 shares worth $4.24M. The position accounts for 0.8% of the portfolio, ranked #58.

Thrive Capital Management (Pennsylvania) first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.24M in Q1 2026. 881 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Thrive Capital Management (Pennsylvania) held 7,824 shares of United Therapeutics worth $4.24M as of Q2 2026.
  • Thrive Capital Management (Pennsylvania) bought 672 United Therapeutics shares in Q2 2026, an estimated $378K.
  • United Therapeutics made up 0.8% of Thrive Capital Management (Pennsylvania)'s portfolio in Q2 2026, its #58 holding.
  • Thrive Capital Management (Pennsylvania) first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Thrive Capital Management (Pennsylvania)'s United Therapeutics position peaked at $4.24M in Q1 2026.
  • 881 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Thrive Capital Management (Pennsylvania)'s 13F filing for Q2 2026, filed 5 Aug 2026.